BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal carcinomas response better to X-ray therapy (XRT) than HPV-negative disease. Whether HPV status influences the sensitivity of head and neck cancer cells to proton therapy or the relative biological effectiveness (RBE) of protons versus XRT is unknown. METHODS: Clonogenic survival was used to calculate the RBE; immunocytochemical analysis and neutral comet assay were used to evaluate unrepaired DNA double-strand breaks. RESULTS: HPV-positive cells were more sensitive to protons and the unrepaired double-strand breaks were more numerous in HPV-positive cells than in HPV-negative cells (p < .001). Protons killed more cells than did XRT at all fraction sizes (all RBEs > 1.06). Cell line type and radiation fraction size influenced the RBE. CONCLUSION: HPV-positive cells were more sensitive to protons than HPV-negative cells maybe through the effects of HPV on DNA damage and repair. The RBE for protons depends more on cell type and fraction size than on HPV status.
BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal carcinomas response better to X-ray therapy (XRT) than HPV-negative disease. Whether HPV status influences the sensitivity of head and neck cancer cells to proton therapy or the relative biological effectiveness (RBE) of protons versus XRT is unknown. METHODS: Clonogenic survival was used to calculate the RBE; immunocytochemical analysis and neutral comet assay were used to evaluate unrepaired DNA double-strand breaks. RESULTS:HPV-positive cells were more sensitive to protons and the unrepaired double-strand breaks were more numerous in HPV-positive cells than in HPV-negative cells (p < .001). Protons killed more cells than did XRT at all fraction sizes (all RBEs > 1.06). Cell line type and radiation fraction size influenced the RBE. CONCLUSION:HPV-positive cells were more sensitive to protons than HPV-negative cells maybe through the effects of HPV on DNA damage and repair. The RBE for protons depends more on cell type and fraction size than on HPV status.
Authors: Jessica M Molkentine; David P Molkentine; Kathleen A Bridges; Tongxin Xie; Liangpeng Yang; Aakash Sheth; Timothy P Heffernan; David A Clump; Alma Z Faust; Robert L Ferris; Jeffrey N Myers; Mitchell J Frederick; Kathryn A Mason; Raymond E Meyn; Curtis R Pickering; Heath D Skinner Journal: Int J Radiat Biol Date: 2020-02-25 Impact factor: 2.694
Authors: Michael T Spiotto; Cullen M Taniguchi; Ann H Klopp; Lauren E Colbert; Steven H Lin; Li Wang; Mitchell J Frederick; Abdullah A Osman; Curtis R Pickering; Steven J Frank Journal: Semin Radiat Oncol Date: 2021-10 Impact factor: 5.421
Authors: Nicolette Taku; Li Wang; Adam S Garden; David I Rosenthal; G Brandon Gunn; William H Morrison; C David Fuller; Jack Phan; Jay P Reddy; Amy C Moreno; Michael T Spiotto; Gregory Chronowski; Shalin J Shah; Lauren L Mayo; Neil D Gross; Renata Ferrarotto; X Ronald Zhu; Xiaodong Zhang; Steven J Frank Journal: Curr Treat Options Oncol Date: 2021-06-04
Authors: Elisabeth Mara; Monika Clausen; Suphalak Khachonkham; Simon Deycmar; Clara Pessy; Wolfgang Dörr; Peter Kuess; Dietmar Georg; Sylvia Gruber Journal: Med Phys Date: 2020-05-15 Impact factor: 4.071